Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men2021 · 31 citations
2. 2Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition2018 · 10,878 citations
3. 3Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance2021 · 75 citations
4. 4A prospective real-world analysis of erenumab in refractory chronic migraine2020 · 199 citations
5. 5Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study2020 · 131 citations